1. In Vivo
  2. >>Leadership

Mogrify: Using Big Data To Transform Development Of Cell Therapies

 
• By Lucie Ellis-Taitt

Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.

Stem cells

UK-based Mogrify, Ltd., which emerged from stealth mode in 2019, is using a big data-based platform technology to transform the development of ex vivo cell therapies and pioneer a new class of in vivo reprogramming therapies. The company boasts Jane Osbourn, former vice president of R&D at MedImmune, as its chair, and Darrin Disley, former CEO of gene-editing firm Horizon Discovery Group PLC, as its CEO.

In May 2019, Karin Schmitt joined the company as chief business officer to lead Mogrify’s commercial operations and its R&D...

More from C-Suite Speaks

How Rapport Transferred A Decade Of Big Pharma Neuroscience Expertise To Biotech

 
• By David Wild

Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.

Does ReproNovo’s $65m Raise Signal An Oasis In The Fertility Investment Desert?

 
• By Jo Shorthouse

ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.

Moderna Veteran Launches Icelandic mRNA Firm Despite US Retreat

 
• By David Wild

Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

More from Leadership

Podcast: Tevard CEO Sees Hope For His Daughter In Company’s tRNA Platform

 
• By David Wild

Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.

Execs On The Move: July 2025

 
• By In Vivo Team

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Rising Leaders 2025: How Christina Smolke Turned Research Into Real World Impact

 
• By David Wild

The Stanford professor-turned-CEO's 15-year journey demonstrates how scientific vision and focused leadership can revolutionize pharmaceutical supply chains.